Santinami, M.

patient interferon group melanoma survival observation treatment table number cancer variant interferon group observation group sample hospital study recurrence-free survival allele pegylated metastasis-free survival control trial event analysis university centre stage recurrence-free e ffect disease association signi iceland icelandic adjuvant value eortc spain metastasis-free death hazard department population nodal ratio nature tumour susceptibility g 138e ficant signi ficant phase effect pigmentation type 2 diabetes randomisation month duration t allele genetic involvement toxicity bcc risk analyses frequency individual lymph haplotype recurrence randomised number 8 metastase nodal involvement radboud university nijmegen basal stage iii melanoma nodal disease p value lymph nodes adjuvant therapy